Literature DB >> 25150606

First case report of acute myeloid sarcoma post renal transplant.

M AlGhunaim1, A AlSuwaida1, S N Zaidi2, H Kfoury3.   

Abstract

BACKGROUND: Although lymphoproliferative disorders are well-described and known entities post renal transplantation, acute myeloid sarcoma is a rare if ever reported occurrence in this setting. Immunosuppressive therapy is thought to be the main culprit in these cases. CASE REPORT: A 51-year-old man underwent renal transplantation 3.5 years earlier from a living unrelated donor. His posttransplant history was relevant for a road traffic accident after which a rise in the serum creatinine warranted 4 renal biopsies over a period of 7 months. The biopsies showed mainly acute tubular injury with sharp increase of the interstitial fibrosis and tubular atrophy between the first and the last biopsies. The patient was put on hemodialysis for 7 months, after which the allograft started functioning. The patient was followed a routinely, until he re-presented with increased creatinine and was found to have intra- and perirenal masses. Biopsies revealed acute myeloid sarcoma. The patient was started on fludarabine and cytosine arabinoside followed by All-trans retinoic acid and arsenic trioxide.
CONCLUSIONS: The patient was disease free on his last positron emission tomography 1 year after the initial diagnosis.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25150606     DOI: 10.1016/j.transproceed.2014.02.007

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  2 in total

1.  A case of ureteral myeloid sarcoma post-renal transplantation.

Authors:  Liang Ying; Lei Tian; Yuanyuan Xie; Qin Wang; Xiajing Che; Jiayi Yan; Lijing Shen; Honghui Huang; Fangyuan Chen; Ming Zhang; Zhaohui Ni; Shan Mou
Journal:  BMC Nephrol       Date:  2018-02-27       Impact factor: 2.388

2.  Case report: Rare myeloid sarcoma development following renal transplantation with KRAS and DNMT3A gene mutations.

Authors:  Danyang Wu; Xiaoxuan Lu; Xiaojing Yan; Ran Gao
Journal:  Diagn Pathol       Date:  2021-08-31       Impact factor: 2.644

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.